Skip to content

Paclitaxel injection therapy for pancreatic cyst

Study of endoscopic ultrasonography-guided Paclitaxel injection therapy for patients with pancreatic cystics lesion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041220072
Enrollment
20
Registered
2022-10-14
Start date
2023-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cystics lesion

Interventions

Paclitaxel injection under endoscopic ultrasonography for pancreatic cystic lesions.

Sponsors

Hara Kazuo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 years or older and 75 years or younger at the time of obtaining informed consent. 2.Patients who given their written consent to participate in this study. 3.Patients diagnosed with the pancreatic cystic lesion. 4.Patients with cyst diameter of 10 mm or more and less than 50 mm measuring by CT or MRI. 5.Patients with unilocular or oligolocular (4 or fewer locules) cyst morphology. 6.Patients whose performance status are 0 to 1. 7.Patients who are not indicated for surgery or refuse surgery in spite of having a certain degree of prognosis.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of allergy to paclitaxel. 2.Patients with cystic lesions obviously suspected of malignancy in the image findings. 3.Patients with cystic lesions obviously suspected of pseudocyst or retention cyst in the image findings. 4.The blood test results within 28 days before registration correspond to the following. (1)Prothrombin time = 1.5. (2)Platelet count <= 50000/mm3 5.Patients taking 2 or more antithrombotic drugs. 6.Patients who are pregnant or have possibility of pregnancy. 7.Patients who are not expected to survive for at least 5 years. 8.Patients who are deemed unsuitable for participating in this study for other reasons.

Design outcomes

Primary

MeasureTime frame
To confirm the safety of endoscopic ultrasound-guided paclitaxel infusion therapy for pancreatic cystic lesions.

Secondary

MeasureTime frame
To confirm the efficacy of endoscopic ultrasound-guided paclitaxel infusion therapy for pancreatic cystic lesions.

Contacts

Public ContactNozomi Okuno

Aichi Cancer Center Hospital

nokuno@aichi-cc.jp+81-52-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026